FDA clears kidney transplant rejection drug from Astellas

07/22/2013 | PharmaTimes (U.K.) · MedPage Today (free registration)

Astellas Pharma obtained the FDA's approval to market Astragraf XL, an extended-release version of the firm's Prograf, or tacrolimus, for prevention of kidney transplant rejection. The approval makes Astragraf XL the first once-daily tacrolimus formulation available to kidney transplant patients in the U.S. The approval was based on data from two late-stage trials involving 1,093 patients.

View Full Article in:

PharmaTimes (U.K.) · MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations